Replimune Group Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Sush Patel

Chief executive officer

US$2.6m

Total compensation

CEO salary percentage	17.2%
CEO tenure	no data
CEO ownership	0.04%
Management average tenure	less than a year
Board average tenure	5.9yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Sush Patel's remuneration changed compared to Replimune Group's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	n/a	n/a	-US$210m
Sep 30 2023	n/a	n/a	-US$199m
Jun 30 2023	n/a	n/a	-US$182m
Mar 31 2023	US$3m	US$447k	-US$174m
Dec 31 2022	n/a	n/a	-US$157m
Sep 30 2022	n/a	n/a	-US$147m
Jun 30 2022	n/a	n/a	-US$133m
Mar 31 2022	US$7m	US$394k	-US$118m

Compensation vs Market: Sush's total compensation ($USD2.60M) is above average for companies of similar size in the German market ($USD1.02M).

Compensation vs Earnings: Sush's compensation has been consistent with company performance over the past year.

CEO

Sush Patel (52 yo)

no data

Tenure

US$2,595,003

Compensation

Dr. Sushil Patel Ph.D. served as the Chief Commercial Officer at Replimune Group, Inc. since May 3, 2021 and serves as its Chief Strategy Officer. He served as the Head of global oncology for lung cancer,...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Philip Astley-Sparke	Executive Chairman	9.3yrs	US$3.65m	2.1% $ 7.7m
Sushil Patel	Chief Executive Officer	no data	US$2.60m	0.041% $ 151.7k
Robert Coffin	Founder	no data	US$5.72m	2.82% $ 10.4m
Emily Hill	Chief Financial Officer	less than a year	no data	no data
Andrew Schwendenman	Chief Accounting Officer & Treasurer	less than a year	no data	0.0046% $ 16.7k
Christopher Sarchi	Chief Commercial Officer	1.3yrs	no data	0.014% $ 50.9k
Konstantinos Xynos	Chief Medical Officer	1.3yrs	no data	0.081% $ 296.9k
Paul Bullock	Chief Manufacturing Officer & Framingham Site Head	less than a year	no data	no data

0.3yrs

Average Tenure

52yo

Average Age

Experienced Management: 7R8's management team is not considered experienced ( 0.3 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
Philip Astley-Sparke	Executive Chairman	9.3yrs	US$3.65m	2.1% $ 7.7m
Robert Coffin	Founder	9.3yrs	US$5.72m	2.82% $ 10.4m
Joseph Slattery	Independent Director	6.5yrs	US$255.96k	0.011% $ 39.9k
Hyam Levitsky	Independent Non-Executive Director	5.9yrs	US$251.96k	0% $ 0
Paolo Pucci	Independent Director	4yrs	US$251.96k	0% $ 0
Kapil Dhingra	Independent Director	6.8yrs	US$252.96k	0% $ 0
Christy Oliger	Independent Director	2.3yrs	US$248.46k	no data
Dieter Weinand	Independent Chairman of the Board	5.8yrs	US$371.44k	0% $ 0
Veleka Peeples-Dyer	Independent Director	less than a year	no data	no data

5.9yrs

Average Tenure

58yo

Average Age

Experienced Board: 7R8's board of directors are considered experienced (5.9 years average tenure).

Replimune Group Management

Management criteria checks 2/4

Key information

Recent management updates

Replimune Group, Inc. Announces Management Changes

Replimune Group, Inc. Announces the Appointment of Emily Hill as Chief Financial Officer

Replimune Group, Inc Announces Appointment of Emily Hill as Chief Financial Officer

Replimune Group, Inc., Annual General Meeting, Sep 06, 2023

Replimune Group, Inc. Announces Sander Slootweg Will Depart from Its Board of Directors

Replimune Group, Inc. Appoints Veleka R. Peeples-Dyer to Its Board of Directors

Recent updates

Replimune Group, Inc. Announces Management Changes

Replimune Group, Inc. Shares Initial Primary Analysis Results from CERPASS Clinical Trial in Advanced Cutaneous Squamous Cell Carcinoma and Presents New Data from IGNYTE Clinical Trial of RP1 in Anti-PD1 Failure Melanoma and Non-Melanoma Skin Cancers

Replimune Group, Inc. Announces the Appointment of Emily Hill as Chief Financial Officer

Replimune Group, Inc Announces Appointment of Emily Hill as Chief Financial Officer

Replimune Group, Inc. has completed a Follow-on Equity Offering in the amount of $6.7 million.

Replimune Group, Inc., Annual General Meeting, Sep 06, 2023

Replimune Group, Inc. Announces Sander Slootweg Will Depart from Its Board of Directors

No longer forecast to breakeven

Replimune Group, Inc. Appoints Veleka R. Peeples-Dyer to Its Board of Directors

Replimune Group, Inc. Presents RP1 Data from the IGNYTE Anti-PD1 Failure Melanoma Cohort and RP2 Data in Uveal Melanoma at the 2023 American Society of Clinical Oncology Annual Meeting

CEO & Director recently sold €298k worth of stock

No longer forecast to breakeven

Insufficient new directors

Replimune Group, Inc. Announces Executive Appointments

Now 23% undervalued

Replimune Announces Positive Initial Data from the Anti-PD1 Failed Melanoma Cohort of the IGNYTE Clinical Trial & an RP2/3 Program Update

Replimune Group, Inc. announced that it has received $200 million in funding from Hercules Capital, Inc. and other investors

Replimune Group, Inc., Annual General Meeting, Sep 07, 2022

Replimune Group, Inc.(NasdaqGS:REPL) dropped from Russell 2000 Growth Index

Replimune Group, Inc. Announces the Resignation of Jason Rhodes from Its Board of Directors

Chief Commercial Officer recently sold €150k worth of stock

Replimune Group, Inc. Announces Updated Data from Completed Cohorts of the Phase 2 Part of the IGNYTE Clinical Trial in Non-Melanoma Skin Cancer (Nmsc) and Melanoma

Replimune Group, Inc. Announces Departure of Dr. Otello Stampacchia from its Board of Directors

Now 22% undervalued after recent price drop

Chief Medical Officer Andrea Pirzkall has left the company

Replimune Group, Inc.(NasdaqGS:REPL) dropped from Russell 3000E Index

Replimune Provides Data Update from its RP1 (vusolimogene oderparepvec) and RP2 Programs and Announces Plans to Expand the Development of RP2/3 Beyond Phase 1

Forecast to breakeven in 2026

Replimune Provides a Regulatory Update for its Registration- Directed Clinical Trials Evaluating RP1 in Combination with Libtayo® (cemiplimab) for the Treatment of CSCC & Evaluating RP1 in Combination with Opdivo® (nivolumab) in anti-PD1 Failed Melanoma

New 90-day low: €30.40

Replimune Group, Inc. Announces First Patient Dosed with RP3 in a Phase 1 Clinical Trial in Patients with Advanced Solid Tumors

New 90-day high: €41.20

Replimune Group Inc. Announces Poster Presentations at the SITC 2020 Annual Meeting and a Presentation at the SITC 2020 Annual Meeting Virtual Press Conference

New 90-day high: €36.20

Replimune Group, Inc. Appoints Tanya Lewis to its Board of Directors, Effective November 2, 2020

Replimune Group, Inc. Announces Initial Clinical Data of Rp2 and Updated Clinical Data of RP1

New 90-day high - €21.40

Replimune Group, Inc. has completed a Follow-on Equity Offering in the amount of $30 million.

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age